AMG 794, a Claudin 6-targeted half-life extended (HLE) bispecific T cell engager (BITE®) molecule for non-small cell lung cancer and epithelial ovarian cancer.

被引：0
|
作者：
Pham, Elizabeth [1 ]
Henn, Anja [2 ]
Sable, Beate [3 ]
Wahl, Joachim [2 ]
Conner, Kip [1 ]
Matthes, Katja [2 ]
Gupta, Shivani [1 ]
Yabut, Rodolfo [1 ]
Aeffner, Famke [1 ]
Wilson, Kristin Lewis [1 ]
Anlahr, Jonas [2 ]
Dahlhoff, Christoph [2 ]
Kale, Vijay [1 ]
Friedrich, Matthias [2 ]
Raum, Tobias [2 ]
Kufer, Peter [2 ]
Coxon, Angela [3 ]
Stienen, Sabine [2 ]
Bailis, Julie M. [1 ]
机构：
[1] Amgen Inc, San Francisco, CA USA
[2] Amgen Res Munich GmbH, Munich, Germany
[3] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5202
引用
收藏
页数：2
相关论文
共 50 条
  • [1] AMG 757, a Half-Life Extended Bispecific T-Cell Engager (HLE BiTE® Immune Therapy) Targeting DLL3, for the Treatment of Small Cell Lung Cancer
    Cooke, K.
    Estrada, J.
    Zhan, J.
    Werner, J.
    Bailis, J.
    Hughes, P.
    Shetty, A.
    Canon, J.
    Smit, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S343 - S344
  • [2] Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC).
    Owonikoko, Taofeek Kunle
    Borghaei, Hossein
    Champiat, Stephane
    Paz-Ares, Luis G.
    Govindan, Ramaswamy
    Boyer, Michael J.
    Johnson, Melissa Lynne
    Udagawa, Hibiki
    Hummel, Horst-Dieter
    Salgia, Ravi
    Blackhall, Fiona Helen
    Boosman, Rene J.
    Lai, Wei-Chu Victoria
    Dowlati, Afshin
    Vokes, Everett E.
    Hann, Christine L.
    Chiang, Anne C.
    Endraca, Marichu
    Soman, Neelesh
    Smit, Marie-Anne Damiette
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] THE DLL3-TARGETED HALF-LIFE EXTENDED BISPECIFIC T CELL ENGAGER (HLE BITE®) IMMUNE-ONCOLOGY THERAPY AMG 757 HAS POTENT ANTITUMOR ACTIVITY IN NEUROENDOCRINE CANCER
    Cooke, Keegan
    Estrada, Juan
    Zhan, Jinghui
    Werner, Jonathan
    Lee, Fei
    Shetty, Aditya
    Smit, Marie-Anne Damiette
    Salvati, Mark
    Bailis, Julie
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A376 - A377
  • [4] Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC).
    Smit, Marie-Anne Damiette
    Borghaei, Hossein
    Owonikoko, Taofeek Kunle
    Hummel, Horst-Dieter
    Johnson, Melissa Lynne
    Champiat, Stephane
    Salgia, Ravi
    Udagawa, Hibiki
    Boyer, Michael J.
    Govindan, Ramaswamy
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer
    Giffin, Michael J.
    Cooke, Keegan
    Lobenhofer, Edward K.
    Estrada, Juan
    Zhan, Jinghui
    Deegen, Petra
    Thomas, Melissa
    Murawsky, Christopher M.
    Werner, Jonathan
    Liu, Siyuan
    Lee, Fei
    Homann, Oliver
    Friedrich, Matthias
    Pearson, Joshua T.
    Raum, Tobias
    Yang, Yajing
    Caenepeel, Sean
    Stevens, Jennitte
    Beltran, Pedro J.
    Canon, Jude
    Coxon, Angela
    Bailis, Julie M.
    Hughes, Paul E.
    CLINICAL CANCER RESEARCH, 2021, 27 (05) : 1526 - 1537
  • [6] Antitumor activity of AMG757, a half-life extended (HLE) bispecific T-cell engager (BiTE®) immune therapy targeting DLL3, in human PDX and orthotopic mouse models of small cell lung cancer (SCLC)
    Cooke, Keegan
    Estrada, Juan
    Zhan, Jinghui
    Werner, Jonathan
    Caenepeel, Sean
    Giffin, Mike
    Bailis, Julie M.
    Coxon, Angela
    Hughes, Paul E.
    Canon, Jude
    CANCER RESEARCH, 2020, 80 (16)
  • [7] A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE®) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer
    Lordick, F.
    Buxo Orra, E.
    Cervantes, A.
    Dayyani, F.
    Rocha-Lima, C.
    Greil, R.
    van Laarhoven, H.
    Lorenzen, S.
    Kischel, R.
    Shitara, K.
    Chao, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S114 - S114
  • [8] Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)
    Tran, B.
    Horvath, L.
    Dorff, T.
    Rettig, M.
    Lolkema, M. P.
    Machiels, J-P.
    Rottey, S.
    Autio, K.
    Greil, R.
    Adra, N.
    Lemech, C.
    Minocha, M.
    Cheng, F-C.
    Kouros-Mehr, H.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S507 - S507
  • [9] Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer.
    Chao, Joseph
    Buxo, Elvira
    Cervantes, Andres
    Dayyani, Farshid
    Rocha Lima, Caio Max Sao Pedro
    Greil, Richard
    Van Laarhoven, Hanneke W. M.
    Lorenzen, Sylvie
    Heinemann, Volker
    Kischel, Roman
    Shitara, Kohei
    Lordick, Florian
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Combination of AMG 160, a PSMA x CD3 half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, with an anti-PD-1 antibody in prostate cancer (PCa)
    Paweletz, Katherine L.
    Li, Shyun
    Bailis, Julie M.
    Juan, Gloria
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345